Formulation of apomorphine for the treatment of Parkinson
Parkinson’s disease is a chronic debilitating disease that affects approximately 1% of the population over the age of 60. Apomorphine, as a potent dopamine receptor agonist, is used to treat patients who have become poorly responsive to treatment or have developed adverse side effects associated with chronic levodopa treatment.
Although apomorphine is a very effective drug, its effect on administration to patients is limited to 30-40 minutes. This is due to its high instability, limited pharmacokinetics, low bioavailability and rapid clearance from plasma; to date it is in fact necessary to administer apomorphine parenterally, with inconvenient and technically difficult methods of administration. The proposed formulation consists of a toxicity-free polysaccharide nanostructure capable of incorporating apomorphine, ensuring its stabilization and release in physiological environments for over 24 hours following oral administration.
- Treatment of patients with Parkinson’s disease poorly responsive to treatment with levodopa;
- Reduction of “off” conditions that may occur in Parkinsonian patients;
- Treatment of Parkinson’s disease in addition to standard therapy, in order to reduce levodopa dosages and the consequences related to the chronic levodopa syndrome.
- Stabilization of apomorphine;
- Use of nano-vectors free of any form of toxicity;
- Prolonged release of the active ingredient;
- Oral administration of apomorphine.